Diagnosis of Combined Adenocarcinoma Small Cell Lung Cancer By Endobronchial Ultrasound Transbronchial Needle Aspiration
No abstract available
We describe two patients with advanced non ‐small‐cell lung cancer (NSCLC), including one in whom the definitive diagnosis of pulmonary pleomorphic carcinoma (PPC) was made by histopathology of the resected tumour and another in whom the diagnosis of “favor adenocarcinoma containing sarcomatoid components” was made by tissue biopsy. Both were resistant to first line platinum‐based chemotherapy, but responded dramatically to second line nivolumab therapy. We present two cases of pulmonary pleomorphic carcinoma (PPC) treated with Nivolumab. A 57 ‐year‐old man presented with a 3.5‐cm mass in the left l...
Conclusion: Positive and negative predictive value of cytology was 95.3% and it was even 100% for well to moderately differentiated tumors. There was a tendency to sub-classify poorly differentiated SqCC as AC. Papanicolaou stain increased the diagnostic accuracy of SqCC. The combined tumor rate was 4% and after recognizing a tumor component, the second component was missed if the slide examination was terminated prematurely.
ConclusionThe study demonstrated that EBUS ‐TBNA provides adequate material for mutation analysis in patients with newly diagnosed adenocarcinoma or NOS lung cancer.This article is protected by copyright. All rights reserved.
Conclusions: Our study has illustrated EBUS-TBNA cytology with ROSE can achieve accurate subtyping of NSCLC and a high proportion of sufficient material for molecular analysis. In addition our NSCLC-NOS rate (8.6%)is lower than UK national average (9%) in 2017.References: 1- Royal College of Physicians. National Lung Cancer Audit annual report 2017
Conclusion: Our findings indicate accurate PD-L1 assessment of cytology specimens may be obtained by EBUS when cell block specimens have adequate cellular content for assessment. False negative results may be seen in inadequate specimens (
Conclusions: CNB and TFNA are useful in the diagnosis of pulmonary neoplasia. The percentage of diagnosis of malignancy of TFNA in relation to CNB offers room for improvement in our centre. These procedures are tolerated well and have a low rate of complications.
Endoscopic ultrasound (with bronchoscope) fine needle aspiration (EUS-B-FNA) has been recognized as a useful and safe technique in sampling mediastinal lymph nodes. Few data are available on its accuracy in diagnosing pulmonary parenchymal lesions adjacent to the esophagus.We performed an observational, retrospective study aimed to evaluate accuracy and safety of EUS-B-FNA for lung parenchymal abnormalities, in two Italian reference centers. Furthermore, impact of rapid on-site evaluation (ROSE) and lesion anatomical site (i.e. lobe) on diagnostic yield were assessed.From November 2016 to January 2018, 21 patients (52.4% m...
Authors: Bellinger CR, Sharma D, Dotson T, Ruiz J, Parks G, Haponik EF Abstract OBJECTIVES: Targeted therapies for non-small-cell lung cancers (NSCLCs) are based on the presence of driver mutations such as epidermal growth factor receptor (EGFR) and the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation. Endobronchial ultrasound-guided-transbronchial needle aspiration (EBUS-TBNA) is a first-line modality for diagnosing and staging NSCLC. A quality improvement protocol maximizing tissue acquisition for molecular analysis has not been previously described. METHODS...
ConclusionsThis study demonstrates the feasibility ofEGFR mutation analysis with both cell block and LBC, with an excellent concordance between the two methods. Considering that the majority of advanced NSCLCs are diagnosed on cytology specimens, LBC is feasible and needs to be implemented for ancillary tests (immunocytochemistry, molecular analysis).
Conclusion Tissue samples obtained through EBUS-TBNA are sufficient for pathological diagnosis and genetic analysis of lung cancer. The pathology type of sample affected genotyping efficacy. DOI: 10.3779/j.issn.1009-3419.2018.09.04